IGCS Video Pearls
<ѻý class="page-description">Video Pearls from the International Gynecologic Cancer Societyѻý>Next step for avutometinib/defactinib combination is going forward with phase III trial
December 5, 2023
Response rates of 14% alone and 18% in combination with checkpoint inhibitor
November 28, 2023
"But I don't think it closes the door" on this class of drugs, says Ritu Salani, MD
November 21, 2023
<ѻý class="section_title"> Latest OB/Gyn Meeting Coverageѻý>
-
ASRM: American Society for Reproductive Medicine
October 2024
-
TMS: The Menopause Society
September 2024
-
ACOG: American College of Obstetricians and Gynecologists
May 2024
-
SGO: Society of Gynecologic Oncology
March 2024